Economic Costs Attributed to Diagnosed Diabetes in Each U.S. State and the District of Columbia: 2021
Diabetes Care · 2025
DOI: 10.2337/dc24-0832 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Care, 2025. Verfasst von Olga A Khavjou und 7 weiteren Autor:innen. Beteiligte Einrichtung: RTI International, Research Triangle Park, NC. Hauptthemen laut MEDLINE: Diabetes Mellitus, Health Care Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NCCDPHP CDC HHS, National Center for Chronic Disease Prevention and Health Promotion.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To update state-specific estimates of diabetes-attributable costs in the U.S. and assess changes in spending from 2013 to 2021. RESEARCH DESIGN AND METHODS We used an attributable fraction approach to estimate direct medical costs of diagnosed diabetes using the 2021 State Health Expenditure Accounts, the 2021 Behavioral Risk Factor Surveillance System, and the Centers for Medicare and Medicaid Services 2018–2019 Minimum Data Set. We estimated diabetes-attributable productivity losses from morbidity and mortality using the 2016–2021 National Health Interview Survey and the 2021 mortality data from the Centers for Disease Control and Prevention. Costs were adjusted to 2021 U.S. dollars. RESULTS Total diabetes-attributable cost in 2021 was $640 billion ($335 billion in direct medical costs and $305 billion in indirect costs). The median state-level total diabetes-attributable cost was $8.2 billion (range $842 million to $81 billion). The median state-level per-person cost was $21,082, ranging from $17,452 to $37,090. Total diabetes-attributable cost increased by a median of 33% between 2013 and 2021, ranging from 16% to 68% across states. Medical costs increased by 50% overall (range 33–79%) and by 27% (range 15–41%) for per person with diabetes. Costs paid by Medicaid experienced the highest increase between 2013 and 2021 (median 153%; range 41–483%). CONCLUSIONS State economic costs of diagnosed diabetes are substantial and increased over the last decade. These costs and their growth vary considerably across states. These findings may help state policymakers in developing evidenced-based public health interventions in their respective states to prevent and control the prevalence of diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- RTI International, Research Triangle Park, NC.
- Centers for Disease Control and Prevention, Atlanta, GA.
- Goldbelt C6, LLC, Chesapeake, VA.
ORCID-Profile: Olga A Khavjou, Simon J Neuwahl, Thomas J Hoerger, Ping Zhang
Förderung
- NCCDPHP CDC HHS
- National Center for Chronic Disease Prevention and Health Promotion
Zitieren
APA
Khavjou, O. A., Sun, M., D'Angelo, S. R., Neuwahl, S. J., Hoerger, T. J., Cho, P., Myers, K., & Zhang, P. (2025). Economic Costs Attributed to Diagnosed Diabetes in Each U.S. State and the District of Columbia: 2021. Diabetes Care. https://doi.org/10.2337/dc24-0832
Vancouver
Khavjou OA, Sun M, D'Angelo SR, Neuwahl SJ, Hoerger TJ, Cho P, et al. Economic Costs Attributed to Diagnosed Diabetes in Each U.S. State and the District of Columbia: 2021. Diabetes Care. 2025. doi:10.2337/dc24-0832
BibTeX
@article{Khavjou2025,
author = {Khavjou, Olga A and Sun, Minglu and D'Angelo, Sophia R and Neuwahl, Simon J and Hoerger, Thomas J and Cho, Pyone and Myers, Kristopher and Zhang, Ping},
title = {Economic Costs Attributed to Diagnosed Diabetes in Each U.S. State and the District of Columbia: 2021},
journal = {Diabetes Care},
year = {2025},
doi = {10.2337/dc24-0832}
}
EUVIMED